Bladder Cancer

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner. July 7, 2026

Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC. July 7, 2026

Predictors of residual tumour and recurrence in high-grade NMIBC: insights from a multicenter re-TURBT cohort. July 6, 2026

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer. July 3, 2026

A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels. July 3, 2026

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with High Body Mass Index or Diabetes Mellitus - Beyond the Abstract July 2, 2026

Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease. July 2, 2026

Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer. July 2, 2026

Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity. July 1, 2026

State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK). July 1, 2026

Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary Disease. July 7, 2026

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC). July 6, 2026

The role of microRNAs-23b and 27b in migration, invasion and proliferation of T24 bladder cancer cells. July 6, 2026

Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis. July 3, 2026

Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites. July 3, 2026

Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC. July 2, 2026

Management of High-Risk Non-Muscle-Invasive Bladder Cancer. July 2, 2026

International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer - Beyond the Abstract July 1, 2026

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care. July 1, 2026

Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer. July 1, 2026

Page 1 of 605